Karur Vysya Bank to consider bonus issue alongside Q1 results on July 24
Karur Vysya Bank has informed the stock exchanges that its Board of Directors will consider a proposal to issue bonus shares during its upcoming meeting scheduled on July 24, 2025.
In a filing with the NSE and BSE dated July 19, 2025, the bank stated that the meeting will also take up the unaudited financial results for the quarter ended June 30, 2025, as earlier announced.
The proposal for a bonus issue of equity shares will be discussed and, if approved, will be subject to shareholders' approval in accordance with applicable provisions of law.
Karur Vysya Bank had previously notified that its trading window for insiders has been closed since July 1, 2025, and will remain shut till July 26, 2025, in line with its Code of Conduct for Prevention of Insider Trading.
The outcome of the meeting and further details on the bonus issue will be communicated after the board meeting.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Are West Pharmaceutical Services (WST) Shares Soaring Today
What Happened? Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon session after the company reported strong second-quarter 2025 financial results and raised its full-year outlook. The medical instruments supplier announced net sales of $766.5 million, a 9.2% increase from the prior year, which surpassed analyst expectations. The company's reported earnings per share (EPS) of $1.82 represented a significant beat over the consensus estimate of $1.51. In light of the strong performance, management increased its full-year 2025 financial outlook. West Pharmaceutical Services raised its net sales guidance to a range of $3.040 billion to $3.060 billion and lifted its adjusted-diluted EPS forecast to between $6.65 and $6.85. Additionally, the company's Board of Directors approved a fourth-quarter dividend of $0.22 per share. Is now the time to buy West Pharmaceutical Services? Access our full analysis report here, it's free. What Is The Market Telling Us West Pharmaceutical Services's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for West Pharmaceutical Services and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 6 days ago when the stock dropped 6.3% on the news that several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. West Pharmaceutical Services is down 15.9% since the beginning of the year, and at $276.29 per share, it is trading 20.6% below its 52-week high of $347.87 from January 2025. Investors who bought $1,000 worth of West Pharmaceutical Services's shares 5 years ago would now be looking at an investment worth $1,052. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Business Upturn
4 hours ago
- Business Upturn
Enviro Infra Engineers secures Rs 221.26 crore wastewater treatment projects from BWSSB
Enviro Infra Engineers Limited (NSE: EIEL, BSE: 544290), a well-known name in the water and wastewater treatment space, has landed two major projects from the Bangalore Water Supply and Sewerage Board (BWSSB), together valued at ₹221.26 crore. The new contracts mark a strong move by EIEL to deepen its role in advanced wastewater reuse solutions, particularly focusing on tertiary treatment and ultrafiltration technologies. Under these orders, the company will design and build two sewage treatment plants (STPs) in Bengaluru: A 20 MLD STP featuring tertiary treatment and ultrafiltration for 10 MLD, including 10 years of operations and maintenance. A 15 MLD STP with similar treatment capabilities and 7.5 MLD ultrafiltration, also with a decade-long maintenance contract. Sanjay Jain, Chairman, Enviro Infra Engineers Limited, stated, 'We are proud to have secured these prestigious projects from BWSSB, which not only reinforce our technical capabilities in delivering complex wastewater and tertiary treatment infrastructure but also reflect the trust that BWSSB has placed in us. Our focus remains on delivering high-quality, sustainable, and timely solutions that contribute to the nation's water management and sanitation goals. We are committed to maintaining the highest standards of engineering and execution.' This development reinforces EIEL's commitment to sustainable water solutions, especially in urban areas where water reuse is becoming increasingly critical. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
4 hours ago
- Yahoo
West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance
- Conference Call Scheduled for 8 a.m. EDT Today - EXTON, Pa., July 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend. Second-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $766.5 million increased 9.2%; organic net sales growth was 6.8%. Diluted EPS of $1.82, compared to $1.51 in the same period last year. Adjusted-diluted EPS of $1.84, compared to $1.52 in the same period last year. Updates full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion. Updates full-year 2025 adjusted-diluted EPS guidance range to $6.65 to $6.85, up from the previous range of $6.15 to $6.35. The Company also announces that its Board of Directors has approved a fourth-quarter 2025 dividend of $0.22 per share. The dividend will be paid on November 19, 2025, to shareholders of record as of November 12, 2025. Eric M. Green, President, Chief Executive Officer and Chair of the Board, commented: "I am pleased to report that we exceeded our expectations for the second quarter driven by solid growth in HVP components. This was the result of strong GLP-1 elastomer growth, ongoing momentum in HVP conversion mainly related to Annex 1 projects and the continued normalization of customer ordering patterns. The improved performance was concentrated in higher margin products, which drove strong margin expansion in the quarter. As a result of our strong second quarter performance and favorable foreign exchange, we are increasing our revenue and adjusted-diluted EPS guidance for fiscal year 2025." Proprietary Products Segment Net sales grew by 10.7% to $619.8 million and increased 8.4% on an organic basis. High-Value Product ("HVP") Components were 47% of total company net sales and increased 11.3%, driven by strength in Westar® and NovaChoice® products. Standard Products, 21% of total company net sales, increased by 0.4%. HVP Delivery Devices represented 13% of total company net sales and increased 30.0%, driven mainly by Daikyo Crystal Zenith® and Administration Systems. The Company's Biologics, Pharma and Generics market units each had high-single digit organic net sales growth. Contract-Manufactured Products Segment Contract-Manufactured Products, representing 19% of total company net sales, increased by 3.0% to $146.7 million, or up 0.5% on an organic basis. Segment performance was driven by an increase in sales of self-injection devices for obesity and diabetes, partially offset by a decrease in sales of healthcare diagnostic devices. Financial Highlights (first six months of 2025) Operating cash flow was $306.5 million, an increase of 8.2% over the same period last year. Capital expenditures were $146.5 million, a decrease of 23.2% over the same period last year. Free cash flow (operating cash flow minus capital expenditures) was $160.0 million, an increase from the first six months 2024 free cash flow of $92.4 million. During the first six months of 2025, the Company repurchased 552,593 shares for $134.0 million at an average share price of $242.55 under its share repurchase program. Full-Year 2025 Financial Guidance The Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion. Net sales guidance includes an estimated full-year 2025 tailwind of approximately $59 million based on current foreign currency exchange rates, compared to previous guidance of a headwind of approximately $5 million. Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%. The Company is increasing its full-year 2025 adjusted-diluted EPS guidance range to $6.65 to $6.85, up from the previous range of $6.15 to $6.35. Full-year adjusted-diluted EPS guidance assumes a $0.27 tailwind based on current foreign exchange rates, compared to previous guidance of no impact. This guidance includes EPS of $0.04 associated with first-half 2025 tax benefits from stock-based compensation. Our updated adjusted-diluted EPS guidance incorporates our estimate of $15 to $20 million for the net impact of recently implemented tariffs. For the remaining quarters of the year, our adjusted-diluted EPS guidance range assumes a tax rate of approximately 21% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-half of 2025 would provide a positive adjustment to our full-year adjusted-diluted EPS guidance. Full-year 2025 capital spending guidance is unchanged and is expected to be $275 million. Second-Quarter 2025 Conference CallThe live audio-only webcast will be made available via the Company's Investor Relations website at To participate in the conference call by asking questions to Management, please register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company's website. A replay of the webcast will be available on the Company's website for approximately 90 days after the event. About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. Forward-Looking StatementsThis release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include such words as "raising," "positioned," "updating," "expected," "assumes," "unchanged," "includes," "would," "provide," "anticipated" and other similar terminology. These statements reflect management's current expectations regarding future events, expected tax rates, impacts on tariffs, and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable; customers' changing inventory requirements and manufacturing plans and customer decisions to move forward with our new products and product categories; disruptions or limitations in the Company's manufacturing capacity; average profitability, or mix, of the products we sell; dependence on third-party suppliers and partners; increased raw material, energy and labor costs; fluctuations in currency exchange; the ability to meet development milestones with key customers; and the consequences of other geopolitical events, including tariffs, natural disasters, acts of war, and global health crises. This list of important factors is not all inclusive. For a description of certain additional factors that could cause the Company's future results to differ from those expressed in any such forward-looking statements, see Part I Item 1A, entitled "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the United States Securities and Exchange Commission, including the Company's quarterly reports on Form 10-Q and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Non-U.S. GAAP Financial MeasuresThis release contains certain non-GAAP financial measures, including organic net sales and adjusted-diluted EPS. For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation and excluding the effects of unallocated items are not in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. A reconciliation of these adjusted non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables. WEST PHARMACEUTICAL SERVICES, INC. CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (in millions, except per share data) Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024 Net sales $ 766.5100 %$ 702.1100 %$ 1,464.5100 %$ 1,397.5100 % Cost of goods and services sold 492.664472.167958.765937.367 Gross profit 273.936230.033505.835460.233 Research and development 19.1217.5235.4235.13 Selling, general and administrative expenses 95.91383.012183.913169.712 Other expense (income), net 5.213.3125.826.4— Operating profit 153.720126.218260.718249.018 Interest (income) expense, net (3.5)—(2.5)—(7.2)—(7.1)— Other nonoperating expense (income) 0.2———0.4——— Income before income taxes and equity in net income of affiliated companies 157.020128.718267.518256.118 Income tax expense 30.2421.9354.3438.33 Equity in net income of affiliated companies (5.0)(1)(4.5)(1)(8.4)(1)(8.8)(1) Net income $ 131.817 %$ 111.316 %$ 221.615 %$ 226.616 % Net income per share:Basic $ 1.82$ 1.52$ 3.06$ 3.09 Diluted $ 1.82$ 1.51$ 3.05$ 3.06 Average common shares outstanding 72.273.072.373.3 Average shares assuming dilution 72.573.772.874.0 WEST PHARMACEUTICAL SERVICES REPORTING SEGMENT INFORMATION (UNAUDITED) (in millions) Three Months Ended June 30,Six Months Ended June 30, Net Sales: 2025202420252024 Proprietary Products $ 619.8$ 559.7$ 1,182.8$ 1,119.2 Contract-Manufactured Products 146.7142.4281.7278.3 Consolidated Total $ 766.5$ 702.1$ 1,464.5$ 1,397.5 Gross Profit:Proprietary Products $ 248.3$ 207.0$ 458.5$ 414.1 Contract-Manufactured Products 25.623.047.346.1 Gross Profit $ 273.9$ 230.0$ 505.8$ 460.2 Gross Profit Margin 35.7 %32.8 %34.5 %32.9 % Operating Profit (Loss):Proprietary Products $ 161.7$ 131.0$ 292.3$ 257.3 Contract-Manufactured Products 17.817.231.334.3 Stock-based compensation expense (7.4)(4.3)(8.7)(9.3) General corporate costs (18.4)(17.7)(54.2)(33.3) Reported Operating Profit $ 153.7$ 126.2$ 260.7$ 249.0 Reported Operating Profit Margin 20.1 %18.0 %17.8 %17.8 % Unallocated items 1.60.219.60.4 Adjusted Operating Profit $ 155.3$ 126.4$ 280.3$ 249.4 Adjusted Operating Profit Margin 20.3 %18.0 %19.1 %17.8 % WEST PHARMACEUTICAL SERVICES RECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED) Please refer to "Non-U.S. GAAP Financial Measures" for more information (in millions, except per share data) Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS Three Months ended June 30, 2025 Operating profitIncome tax expenseNet incomeDiluted EPS Reported (U.S. GAAP) $153.7$30.2$131.8$1.82 Unallocated Items:Restructuring and other charges (1) 1.60.41.20.02 Amortization of acquisition-related intangible assets (2) ——0.5— Adjusted (Non-U.S. GAAP) $155.3$30.6$133.5$1.84 Six Months ended June 30, 2025 Operating profitIncome tax expenseNet incomeDiluted EPS Reported (U.S. GAAP) $260.7$54.3$221.6$3.05 Unallocated Items:Restructuring and other charges (1) 19.42.417.00.23 Amortization of acquisition-related intangible assets (2) 0.2—1.10.01 Adjusted (Non-U.S. GAAP) $280.3$56.7$239.7$3.29 Three Months ended June 30, 2024 Operating profitIncome tax expenseNet incomeDiluted EPS Reported (U.S. GAAP) $126.2$21.9$111.3$1.51 Unallocated items:Amortization of acquisition-related intangible assets (2) 0.2—0.70.01 Adjusted (Non-U.S. GAAP) $126.4$21.9$112.0$1.52 Six Months ended June 30, 2024 Operating profitIncome tax expenseNet incomeDiluted EPS Reported (U.S. GAAP) $249.0$38.3$226.6$3.06 Unallocated items:Amortization of acquisition-related intangible assets (2) 0.4—1.40.02 Adjusted (Non-U.S. GAAP) $249.4$38.3$228.0$3.08 (1) During the three and six months ended June 30, 2025, the Company recorded charges of $1.6 million and $19.4 million related to restructuring programs. During the three and six months ended June 30, 2025, the Company recorded $0.2 million and $16.6 million, respectively, of the charge within other expense (income), related to severance and acceleration of depreciation and lease costs in connection with the Company's 2025 restructuring plan. The Company recorded the remaining $1.4 million and $2.8 million, respectively, within selling, general and administrative expenses, related to our plan to optimize the legal structure of the Company and its subsidiaries. (2) During the three and six months ended June 30, 2025 and 2024, the Company recorded $0.0 million and $0.2 million, and $0.2 million and $0.4 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and six months ended June 30, 2025 and 2024, the Company recorded $0.5 million and $0.9 million, respectively, and $0.5 million and $1.0 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo. WEST PHARMACEUTICAL SERVICES RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) Please refer to "Non-U.S. GAAP Financial Measures" for more information (in millions, except per share data) Reconciliation of Net Sales to Organic Net Sales (3) Three Months ended June 30, 2025 ProprietaryCMTotal Reported net sales (U.S. GAAP) $619.8$146.7$766.5 Effect of changes in currency translation rates (12.9)(3.6)(16.5) Organic net sales (Non-U.S. GAAP) (3) $606.9$143.1$750.0 Six Months ended June 30, 2025 ProprietaryCMTotal Reported net sales (U.S. GAAP) $1,182.8$281.7$1,464.5 Effect of changes in currency translation rates (3.1)(1.7)(4.8) Organic net sales (Non-U.S. GAAP) (3) $1,179.7$280.0$1,459.7 (3) Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. WEST PHARMACEUTICAL SERVICES RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) Please refer to "Non-U.S. GAAP Financial Measures" for more information (in millions, except per share data) Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance 2024 Actual2025 Guidance% Change Reported-diluted EPS (U.S. GAAP) $6.69$6.36 to $6.56(4.9%) to (1.9%) Restructuring and other charges 0.020.26 Amortization of acquisition-related intangible assets 0.040.03 Adjusted-diluted EPS (Non-U.S. GAAP) (4) $6.75$6.65 to $6.85(1.5%) to 1.5% Notes: See "Full-year 2025 Financial Guidance" and "Non-U.S. GAAP Financial Measures" in today's press release for additional information regarding adjusted-diluted EPS. (4) We have opted not to forecast 2025 tax benefits from stock-based compensation in upcoming quarters, as they are out of the Company's control. Instead, we recognize the benefits as they occur. In the first six months of 2025, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.04. Any future tax benefits associated with stock-based compensation that we receive in 2025 would provide a positive adjustment to our full-year EPS guidance. In full-year 2024, tax benefits associated with stock-based compensation increased adjusted-diluted EPS by $0.26. WEST PHARMACEUTICAL SERVICES CASH FLOW ITEMS (UNAUDITED) (in millions) Six Months Ended June 30,20252024 Depreciation and amortization $81.4$74.5 Operating cash flow $306.5$283.2 Capital expenditures $146.5$190.8 Free cash flow $160.0$92.4 WEST PHARMACEUTICAL SERVICES FINANCIAL CONDITION (UNAUDITED) (in millions) As of June 30, 2025As of December 31, 2024 Cash and cash equivalents $509.7$484.6 Accounts receivable, net $582.4$552.5 Inventories $421.1$377.0 Accounts payable $239.0$239.3 Debt $202.6$202.6 Equity $2,929.1$2,682.3 Working capital $1,076.3$987.7 Trademark Notices Trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., in the United States and other jurisdictions, unless noted otherwise. Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd. View original content to download multimedia: SOURCE West Pharmaceutical Services, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
